Addressing the challenges in treatment decision making for SMA
In the first part of this episode, we talk to Laurent Servais about the challenges in treatment decision making for spinal muscular atrophy and how they could be addressed (17:46).
In the second part of this episode, Laurent Servais discusses the findings from early-phase studies of anti-myostatin antibodies for the treatment of spinal muscular atrophy, and explores how these drugs may help to address some of the treatment challenges if the benefits are confirmed in phase 3 studies (13:34).
